PolyPid (NASDAQ:PYPD) Trading Up 3.4% – Here’s Why

Posted by Lisa Durand on Jan 22nd, 2025

PolyPid Ltd. (NASDAQ:PYPD – Get Free Report)’s share price was up 3.4% during mid-day trading on Monday . The stock traded as high as $3.33 and last traded at $3.30. Approximately 27,404 shares changed hands during trading, a decline of 38% from the average daily volume of 44,111 shares. The stock had previously closed at $3.19.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on PYPD shares. HC Wainwright lowered their target price on PolyPid from $14.00 to $11.00 and set a “buy” rating on the stock in a research note on Thursday, December 26th. Craig Hallum assumed coverage on PolyPid in a research note on Monday, November 4th. They issued a “buy” rating and a $10.00 price target for the company.

Check Out Our Latest Research Report on PolyPid

PolyPid Trading Down 1.5 %

The firm’s fifty day moving average is $3.14 and its 200-day moving average is $3.39. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.00 and a quick ratio of 1.00. The firm has a market cap of $15.60 million, a price-to-earnings ratio of -0.42 and a beta of 1.32.

Institutional Trading of PolyPid

An institutional investor recently bought a new position in PolyPid stock. Stonepine Capital Management LLC purchased a new position in shares of PolyPid Ltd. (NASDAQ:PYPD – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 138,504 shares of the company’s stock, valued at approximately $476,000. Stonepine Capital Management LLC owned approximately 2.89% of PolyPid as of its most recent filing with the Securities and Exchange Commission (SEC). 26.47% of the stock is owned by institutional investors and hedge funds.

PolyPid Company Profile

(Get Free Report)

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.